PATIENT INTERFACE AND ASPECTS THEREOF

(19)

(11)

EP 3 708 210 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	16.11.2022 Bulletin 2022/46

(45)	Mention of the grant of the patent:
	19.10.2022 Bulletin 2022/42

(21)	Application number: 20172425.9

(22)	Date of filing: 17.07.2014

(51)

International Patent Classification (IPC):

A61M 16/06^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61M 16/06; A61M 16/0666; A61M 16/0683

(54)	PATIENT INTERFACE AND ASPECTS THEREOF PATIENTENSCHNITTSTELLE UND ASPEKTE DAVON INTERFACE POUR PATIENT ET SES ASPECTS

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

17.07.2013 US 201361847452 P
08.05.2014 US 201461990328 P

(43)	Date of publication of application:
	16.09.2020 Bulletin 2020/38

(60)	Divisional application:
	22195457.1

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	14826102.7 / 3021922

(73)	Proprietor: Fisher & Paykel Healthcare Limited
	2013 Auckland (NZ)

(72)	Inventors:
	NICOLSON, Charles 2013 Auckland (NZ) HAMMER, Jeroen 2013 Auckland (NZ) SLIGHT, Matthew Robert Geoff 2013 Auckland (NZ) HUANG, Wen Dong 2013 Auckland (NZ) GARDIOLA, Arvin San Jose 2013 Auckland (NZ)

(74)	Representative: Forresters IP LLP
	Skygarden Erika-Mann-Straße 11 80636 München 80636 München (DE)

(56)

References cited: :

WO-A1-2010/131189

US-A1- 2011 146 685

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).